Tirzepatide | Dual GIP/GLP-1 Research Peptide

Description

Tirzepatide is a synthetic dual GIP/GLP-1 receptor agonist and one of the most advanced metabolic research peptides currently available for preclinical study. By simultaneously activating both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, tirzepatide research models have demonstrated synergistic effects on insulin secretion, glucagon regulation, body weight, and lipid metabolism that exceed those seen with single-receptor agonists.

Preclinical research has investigated tirzepatide in models of type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), obesity, and cardiovascular metabolic risk. Studies in rodent models have explored its effects on adipose tissue reduction, hepatic fat accumulation, beta-cell mass preservation, and energy expenditure pathways. The dual receptor engagement mechanism has made tirzepatide a particularly important tool for researchers studying the complementary roles of GIP and GLP-1 signalling in metabolic homeostasis.

Tirzepatide has a molecular weight of 4,813.46 Da and the molecular formula C225H348N48O68. CAS number: 2023788-19-2. Peptryn’s tirzepatide is manufactured to ≥99% purity by HPLC and mass spectrometry. An independent certificate of analysis from a US laboratory accompanies every batch. Bulk pricing tiers apply automatically.

Storage: Store lyophilized at -20°C. After reconstitution, refrigerate at 2–8°C and use within 28 days. Protect from light.

For laboratory and in vitro research use only. Not intended for human consumption, self-administration, or veterinary use.